Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended March 31, 2024 and reaffirmed its financial guidance for 2024.
- Total operating expenses for the first quarter of 2024 were $274 million, including non-cash stock-based compensation of $37 million.
- Net cash used in operations for the quarter ended March 31, 2024 was $191 million.
- For the full year 2024, the company reaffirms:
Crysvita revenue in the range of $375 million to $400 million. - ET to discuss the first quarter 2024 financial results and provide a corporate update.